Biogen IDEC News

Biogen IDEC News
Biogen IDEC News Image link:
C O N T E N T S:


  • Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, U.S. Bancorp, BlackRock and more.(More...)


  • Shares of Biogen ended the regular trading session up 3%, with Wall Street closely following the release of the study as the drug could position Biogen as a leader in drugs to fight the memory-destroying disease.(More...)
  • Biogen is working on a number of Alzheimer's disease treatments, including aducanumab and a drug partnered with Eisai called BAN2401.(More...)



Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, U.S. Bancorp, BlackRock and more. [1] In early 2005, Tysabri was pulled from the market just a few months after approval by the FDA. The drug, marketed by the company, then known as Biogen Idec Inc., and Elan Pharmaceuticals Inc. of Ireland, was linked to multiple cases of a rare condition called progressive multifocal leukoencephalopathy, or PML. The disease, an infection of the brain, can cause death or severe disability. [2] Three years later, Biogen (then called Biogen Idec) paid $32.5 million upfront to acquire a subsidiary of Neurimmune working on three preclinical neurodegenerative disease antibody programs targeting alpha-synuclein, tau, and TDP-43 ( TAR DNA-binding protein 43). [3] Biogen Inc., formerly Biogen Idec Inc., incorporated on April 1, 1997, is a biopharmaceutical company. [4]

The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. [5] Biogen Idec and Fumapharm AG, a privately held pharmaceutical company, today announced that they have signed a definitive agreement for the acquisition of Fumapharm by Biogen Idec. [6] Law360 (April 27, 2018, 9:36 PM EDT) -- Biogen Idec Inc. must face a False Claims Act lawsuit in Massachusetts after a federal judge on Friday ruled two former employees adequately alleged that the Cambridge-based company paid kickbacks in 2009 and 2010 to doctors who prescribed its multiple sclerosis medications. [7] Mealey's (May 2, 2018, 10:40 AM EDT) -- BOSTON -- A Massachusetts federal judge on April 27 declined to dismiss most of the claims by two whistleblowers that Biogen Idec Inc. violated the False Claims Act by paying illegal kickbacks to doctors to prescribe three multiple sclerosis drugs and causing false claims to be paid by the federal government (United States of America, et al., ex rel. [8]

Michael Bawduniak, et al. v. Biogen Idec, Inc., No. 12-10601, D. Mass., 2018 U.S. Dist. LEXIS 70848). (Opinion available. [8]

In 2017, Biogen Idec generated revenues worth around 12.3 billion U.S. dollars. [9] This statistic shows the revenue and net income of biotechnology company Biogen Idec from 2007 to 2017. [9] BAN2401 is a monoclonal antibody being co-developed by Eisai and Biogen Idec. [10]

This huge jump stemmed from a merger between Biogen and IDEC Pharmaceuticals. [11] Energy usage in Biogen Idec's Data Center in Cambridge, MA was significantly reduced with a zero-impact solution, implemented by ENGIE Services U.S. (ENGIE). [12] UK, received a contract from Biogen Idec in May and pharmaceutical companies to contact Biogen Biogen, a portfolio company Biogen snaps up Tamar in AD deal. [13] April 15, On Thursday, Biogen (BIIB) agreed to license anti whereas UK and Japanese studies suggested a 2 Responses to Leading UK Food Waste AD Company Biogen Acquires Tamar Energy. vice president and managing director of Biogen UK Your email address The best Biogen Idec phone number with tools If you think this information is inaccurate or know of other ways to contact Biogen Idec please let us (UK) Phone 741 Biogen reviews. [13] Whittier Trust Co Of Nevada Inc decreased its stake in Biogen Idec Inc (BIIB) by 12.65% based on its latest 2018Q1 regulatory filing with the SEC. Whittier Trust Co Of Nevada Inc sold 2,023 shares as the company's stock declined 1.31% with the market. [14] Biogen Idec Inc. had 142 analyst reports since July 23, 2015 according to SRatingsIntel. UBS maintained the shares of BIIB in report on Wednesday, July 26 with "Neutral" rating. [15]

Biogen Idec Inc. had 142 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Biogen Inc. (NASDAQ:BIIB) has "Hold" rating given on Thursday, September 28 by Robert W. Baird. [16] Biogen Reports Record Revenues for Both the Full Year and genetic information on 500,000 people in the UK Biobank Biogen Inc. Bekijk het profiel van Colin. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, Get to know Biogen (UK) Ltd CEO & other corporate executives. [13] We also show the fastest phone numbers, email addresses, wait times, and the way to contact Biogen Idec for the highest quality customer care UK clean energy recovery from waste business ENERGOS Holdings Limited has acquired waste to energy business BioGen Power Limited through a share swap arrangement. [13] S. You can share your experiences as well as improve customer support, but its not the beat way to reach Biogen Idec. [13] Biogen Idec Inc. has $450 highest and $268 lowest target. $364.45's average target is 3.05% above currents $353.66 stock price. [17] Biogen Idec Inc. had 142 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has "Hold" rating by RBC Capital Markets on Friday, March 2. [17] Biogen Idec Inc. had 142 analyst reports since July 23, 2015 according to SRatingsIntel. As per Friday, December 18, the company rating was initiated by Atlantic Securities. [14] We also show the fastest phone numbers, email addresses, wait times, and the way to contact Biogen Idec for the highest quality customer care Ancala Partners portfolio company Biogen, CONTACT General Enquiries Tel: 0207 638 9571 Mob: +44 7774 133934 Patrick. [13] Biogen Idec - sales performance and latest news - Top Pharma List - PMLiVE The fastest web-based support from Biogen Idec if you're looking to get help online. [13] Whittier Trust Co decreased Biogen Idec Inc (BIIB) stake by 21.7% reported in 2018Q1 SEC filing. [18] Among 33 analysts covering Biogen Idec Inc. ( NASDAQ:BIIB ), 25 have Buy rating, 0 Sell and 8 Hold. [14]

On the basis of the information available to it, the Office of Fair Trading has decided that the proposed acquisition of Biogen Inc by IDEC Pharmaceuticals Corp does not qualify for investigation under the mergers provisions of the Enterprise Act 2002, because neither the UK turnover test nor the Biogen?s Medical Information Web Site. [13]


Shares of Biogen ended the regular trading session up 3%, with Wall Street closely following the release of the study as the drug could position Biogen as a leader in drugs to fight the memory-destroying disease. [19] Eisai and Biogen revealed new data showing their closely watched experimental drug slowed the worsening of Alzheimer’s disease, but some experts said more testing is needed. [19] Biogen and Japan’s Eisai said they had positive results from a midstage study of an experimental Alzheimer’s drug, though experts said it was too soon to say the drug marks a real advance. [19]

Biogen also announced on Tuesday that it has acquired two neuromuscular drugs, a preclinical product and a drug that is in phase 1a trials, from the privately-held biotechnology company AliveGen Inc. for $27.5 million upfront; AliveGen is also eligible for up to $535 million in additional milestone payments. [19] Shares of Biogen took off following upbeat trial data of an Alzheimer’s treatment. [19] The Wednesday event, detailing phase 2 trial results for the Alzheimer's disease therapy BAN2401, could position Biogen as a leader in the difficult-to-treat disease, with two promising Alzheimer's disease therapies. [19] Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. [19]

Among the companies with shares expected to trade actively in Friday's session are JPMorgan Chase, Caterpillar, Exxon Mobil, Biogen and PriceSmart. [19] Bridgewater lightened up on shares of Biogen Inc., GameStop Corp., and PG&E Corp., among others, and kept large holdings in two major gold-backed ETFs, the iShares Gold Trust and SPDR Gold Trust. [19]

Biogen and partner Eisai have already said that the phase 2 trial had positive results. [19] Shares of Biogen Inc. fell more than 9% late Wednesday after the drug maker, alongside Eisai Co. Ltd., shared data about an experimental drug trial to combat Alzheimer's disease. [19] Biogen Inc. shares rose more than 4% in extremely heavy Wednesday morning trade in advance of a major Alzheimer's disease drug presentation planned for the afternoon. [19] Biogen Inc. shares surged 4.2% in Tuesday premarket trade after the company reported second-quarter profit and revenue beats and raised its 2018 profit and revenue guidance. [19]

Biogen increased its 2018 revenue guidance from a range of between $12.7 billion to $13.0 billion to a range of about $13 billion to $13.2 billion, above the FactSet consensus of $12.96 billion. [19] Shares of Biogen Inc. rose 0.6% in premarket trade Friday, after the biotechnology company disclosed the authorization of a $3.5 billion share repurchase program. [19] The gains came after strong results from both Biogen Inc. and Eli Lilly & Co. [19]

Positive Alzheimer’s data has given Biogen shares a lift, but recent history suggests investors should be careful. [19] Biogen shares have surged 41% over the last three months, compared with a 6.9% rise in the S&P 500 and a 4.4% rise in the Dow Jones Industrial Average. [19]

On Thursday night, Biogen announced surprise successful results from an Alzheimer's drug clinical trial that sent shares of the pharmaceutical company soaring. [20] That long history of false starts helps to explain why positive clinical trial results for a new Alzheimer?s drug reported on Thursday by Biogen and Tokyo-based Eisai sent sent shares of Biogen soaring. [20]

Shares of Biogen are surging Friday, a day after the company and Eisai announced positive results from a Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. [21] Recently, Biogen ( BIIB ) and its partner Eisai ( OTCPK:ESALY ) announced a positive update from the phase 2 study in treating patients with early Alzheimer's disease. [22] Biogen has reached a good feat in obtaining the secondary endpoint from its phase 2 study in treating patients with early Alzheimer's disease. [22]

Biogen has another drug in a phase 3 study treating patients with Alzheimer's known as Aducanumab. [22] Biogen is not only relying on BAN2401 for Alzheimer's treatment, it also has another drug in late-stage development for the disease known as Aducanumab. [22] The good news is that Biogen has achieved something which not many other biotechs have been able to, and that is to show the ability for a drug to slow down the progression if this disease. [22] Biogen grew more dependent on its MS franchise after it spun off its hemophilia drugs into a new company earlier this year. [23] The FDA could approve Celgene Corp. 's rival drug ozanimod next year, which would siphon more sales from Biogen. Mylan NV's cheaper copy of Teva Pharmaceutical Industries Ltd. 's Copaxone is just now hitting the market, which will add to overall pricing pressure and begin impacting Biogen as soon as next quarter. [23] Do Surprising Alzheimer's Disease Results Make Biogen Stock a Smart Buy Now? The clinical trial results are a big deal, but they don't necessarily make the pharmaceutical com. [24] Biogen delivered promising results on a new Alzheimer's disease treatment. [1]

BAN2401 is the first late-stage, anti-amyloid antibody to achieve statistically significant results at 18 months, Biogen reported. [20] What Happened in the Stock Market Today As stocks ended the week on an optimistic note, Biogen reported a successful trial for an Alzheim. [24] Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next. [1] Biogen Posts Double-Digit Profits, Has Cash to Burn Spinal muscular atrophy drug Spinraza makes up for declines in the biotech's multiple sclerosis d. [24] Biogen gets royalties from Roche -- $65 million in the latest quarter -- because it once owned a chunk of that drug. [23]

Biogen posts that BAN2401 met on the ADCOMS secondary endpoint measure in its phase 2 study treating patients with Alzheimer's. [22] Even with the passing of the secondary endpoint from the phase 2 study by Biogen and Eisai, analysts are now predicting a 50% chance that BAN2401 may be eventually be approved. [22]

Back in December of 2017, Biogen and Eisai were not proud of the data. [22]

Why Biogen Stock Slumped in February The biotech company's stock suffered last month after a key change to its ongoing Alzheimer?s dis. [24] Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today Find out why good news elsewhere hurt one of these stocks. [24] Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks. [1] The Fool has written over 600 articles on Biogen. 3 Terrible Stocks for Retirees Healthcare's usually a great sector for retirees, but these stocks just don't fit the bill. [24] That gain added nearly $12 billion in value to Biogen. This gain does make sense though, because the Alzheimer's market is expected to reach about $14.6 billion by 2026. [22] This provides another shot on goal for Biogen in Alzheimer's. [22]

I would hope that if Biogen does initiate its phase 3 study, it doesn't look at the cost when designing it. [22] Novartis' Acquisition of AveXis: Bad News for Biogen? Not only might Biogen be facing a challenger for Spinraza next year, it could be a big challenger. [24] The reason why Biogen may have used that statistical method could have been to create a more adaptive trial design. [22] Biogen had a market value of $63 billion as of Thursday?s close. [21] Biogen's $1 Billion Bet on Ionis Biogen announced it would pay nearly $1 billion for expanded access to Ionis? pipeline. [24]

Biogen shareholders are rejoicing over a clinical trial?s positive results. [21] Biogen has a growing biosimilars business, but that space is becoming increasingly crowded, and  competitors will drive down prices. [23]

Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast. [25] LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. [25]

Why Biogen Inc. Stock Soared 15.2% Today Encouraging clinical results for an experimental Alzheimer's disease drug provide a big boost for. [24] CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial. [25] July 24 Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza. [25] Biogen Inc. 's third-quarter revenue, profit, and sales of a closely watched new medicine all exceeded analyst expectations. [23] Better Buy: Biogen Inc. vs. Amgen Biogen and Amgen have been two of the best performing biotechs for a decade. [24] Is Biogen Inc. a Buy? The biotech has a lot of promise -- but some big risks. [24] Is Biogen Inc. a Buy? Biogen's stock has had an awful 2018 so far. [24]

The stock move added more than $12 billion in value to Biogen shares. [21] Biogen shares were down 6 percent this year through Thursday versus the S&P 500?s 2 percent gain. [21] The analyst reiterated his overweight rating and $400 price target for Biogen shares, representing 34 percent upside to Thursday?s close. [21]

There is something that will reduce the risk of Biogen's Alzheimer's programs. [22] Why Biogen's Stock Is Slumping Today Biogen's highly-anticipated Alzheimer's disease clinical update failed to impress investors. [24] Biogen's stock gained nearly 19.63% to $357.48 per share after the release of the news. [22]

Biogen is working on a number of Alzheimer's disease treatments, including aducanumab and a drug partnered with Eisai called BAN2401. [26] Biogen ( BIIB ) could benefit from a "fear-of-missing-out rally" as it closes in on pivotal data for its Alzheimer's disease treatment, aducanumab, an analyst said this week as he upgraded the stock. [26]

Among drug developers focused on Alzheimer's is Biogen, which today said it has renegotiated a 10-year-old partnership with Neurimmune to develop aducanumab, a Phase III antibody designed to bind to and reduce brain amyloid plaques. [3] Earlier this month, Ionis won a $10 million milestone payment from Biogen for launching a Phase I/IIa trial of IONIS-MAPT Rx designed to evaluate the safety and activity of IONIS-MAPT Rx in approximately 44 mild Alzheimer's disease patients. [3] Biogen, AbbVie pull MS drug after several patients suffer brain inflammation Globe Staff Zinbryta was approved for sale in 2016 and is used by about 3,000 people worldwide. [2] Risks in that segment include rivalry from Roche's ( RHHBY ) drug Ocrevus -- though Biogen gets a royalty on those sales -- and drug-pricing concerns. [26] IONIS-MAPT Rx, an antisense drug which Biogen is co-developing with Ionis Pharmaceuticals. [3] This is not the first time Biogen has withdrawn a drug to treat multiple sclerosis because of safety concerns. [2] "Biogen believes the voluntary worldwide withdrawal of Zinbryta, a treatment for relapsing multiple sclerosis, is in the best interest of patients," said Dr. Alfred Sandrock, executive vice president and chief medical officer at Biogen, which is Massachusetts' largest biotechnology company. [2] In February, Biogen increased the size of a study of aducanumab by 510 patients. [26] Biogen also holds an option to further reduce its future royalties on commercial sales of aducanumab by an additional 5% percent by making an additional one-time $50 million payment to Neurimmune. [3] Biogen said the reworked collaboration will increase its overall profit potential through a 15% reduction in its potential royalty payment on potential commercial sales of aducanumab. [3] The FDA approved Zinbryta for sale in the United States in 2016, Biogen spokesman David Caouette said. [2]

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological. [27] On the stock market today, Biogen slipped 0.2% to close at 293.96. [26] Development of new Alzheimer's disease treatments is the focus of separate collaboration agreements announced today by AbbVie and Biogen. [3] "the Alzheimer's disease market is large enough for Biogen to benefit from a fear of missing out in case positives emerge," he said. [26] "This amended agreement with Neurimmune improves aducanumab's potential value to Biogen as we pursue our strategic goal of leadership in Alzheimer's disease," Biogen CEO Michel Vounatsos said in a statement. [3]

Biogen is expected to report earnings of $5.44/share on $3.06 billion in revenue. [4] Biogen competes with Teva Pharmaceuticals Industries Ltd., Novartis AG, Merck KGaA, Pfizer Inc., Bayer Group, Sanofi, Baxalta, CSL Behring and Emergent Biosolutions, among other biotech companies. [4] In return, Biogen agreed to make a one-time, $150 million payment to Neurimmune, which stated on its website that the money would accelerate the development of its human antibody pipeline through clinical proof of concept. [3] Biogen has since developed a test to determine which MS patients might be most susceptible to the brain infection. [2] Canaccord analyst Sumant Kulkarni updated Biogen to a buy rating from hold, though he trimmed his price target to 335 from 350. [26]

On Thursday's PreMarket Prep, Joel and Dennis were joined by STAT News Senior Writer Adam Feuerstein, who broke down the surprising Alzheimer's drug news from Biogen Inc (NASDAQ: BIIB ), and Chaikin Analytics Chief Market Strategist Dan Russo, who highlighted several sectors he's bullish on right now. [28] Biogen Inc. and an Illinois drugmaker said Friday that they are pulling their new treatment for multiple sclerosis from the market because a number of patients using it have suffered serious brain inflammation. [2] U.K.?s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy. [29]

In an indication that investors were not overly concerned about the drug coming off the market, Biogen shares closed up 1.63 percent, at $286.96. [2] It has gone on to become one of Biogen's top-selling drugs. [2] "That said, we like the potential for the stock to benefit from a fear-of-missing-out rally as more data points crop up on Biogen's high-stakes Alzheimer's disease pipeline." [26] Aducanumab is one of two Phase III Alzheimer's candidates in Biogen's pipeline. [3] "While that risk (of headwinds) still remains, we note that Biogen's prescription share, at least in the U.S., appears to have been stabilizing," he said. [26]

Shares of Biogen jumped 6.42% in the after market trading session on Thursday July 5th, 2018 when the company announced that a joint venture with a Japanese-based biotech firm, Eisai Co., Ltd. working on a drug for early onset Alzheimer?s disease showed significant slowing in mental clinical decline as well as lowering the amount of an amyloid beta that would accumulate in the brain of patients with the debilitating disease. [30] BIIB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Canada Pension Plan Investment Board, Renaissance Technologies LLC, Point72 Asset Management L.P., Putnam Investments LLC, BlackRock Inc., Manning & Napier Group LLC and Smith Asset Management Group LP. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock and Robert W Pangia. [5] Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. [5] Company insiders that own Biogen stock include Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. [5]

MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. [5]

Biogen is one of the world?s leading biotechnology companies, with a focus on developing therapies for serious neurological, autoimmune and rare diseases. [31] Biogen has a market capitalization of $70.50 billion and generates $12.27 billion in revenue each year. [5] Biogen trades on the NASDAQ under the ticker symbol "BIIB." [5]

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. [5] Biogen Inc (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, July, 24th. [5] Biogen Inc. offers products through its sales force and marketing groups. [5]

The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. [5] On average, they anticipate Biogen's stock price to reach $375.5241 in the next twelve months. [5] Biogen's stock is owned by a variety of of institutional and retail investors. [5]

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now. and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys. [11] Perhaps Biogen will make an acquisition this year that could provide a spark for its stock. [11] Roche (NASDAQOTH: RHHBY) licensed the MS drug from Biogen several years ago. [11] How about revenue growth? In 2004, Biogen reported revenue of nearly $1.5 billion -- around 8.7 times bigger than the prior year. [11] Although Biogen reported encouraging results from earlier studies, the landscape is littered with once-promising Alzheimer's treatments that flamed out. [11] Biogen, which has made a name for itself in developing therapies for multiple sclerosis, Alzheimer's disease and dementia, is evolving to develop treatment options for people with nerve pain, stroke and psychiatric diseases. [32] For now, the market is closing watching for data from the Phase III trials of aducanumab, a human monoclonal antibody that Biogen designed to treat Alzheimer's disease. [32] The company's pipeline candidates targeting Alzheimer's disease could be game-changers for patients and for Biogen. [11] Biogen isn?t the only pharmaceutical company interested in using digital to help patients with MS. In March Novartis inked a deal with Pear Therapeutics, a digital health company, to developed two digital therapeutics including one for MS and another for schizophrenia. [33] After taking the helm at Biogen (NSDQ: BIIB ) in 2016, Michel Vounatsos made use of acquisitions and geographic expansion to grow the company. [32]

One big threat will ironically come from a drug Biogen originally developed -- Ocrevus. [11] Even if the prior-year comparisons weren't so difficult to top, there's a big reason Biogen won't have its best year yet in 2018. [11] I guess there's the tiniest of possibilities that Biogen could undergo another merger in 2018 that could give it a larger revenue boost than it had in 2004. [11] Aducanumab (BIIB037) is a monoclonal antibody being developed by Biogen against aggregated forms of beta-amyloid. [10] Biogen has just launched a new app, called Aby, aimed at giving people living with multiple sclerosis (MS) accurate and reliable information about the condition and support. [33]

Biogen Inc. is a Massachusetts-based biotech company, specialized in drugs for neurological disorders, autoimmune disorders and cancer. [9]

There is no scenario under the sun that I can imagine that will make 2018 Biogen's best year ever in terms of stock performance -- and probably not for revenue growth or earnings growth, either. [11] What would it take for 2018 to be Biogen's best year yet? Well, the stock would only have to generate a gain of more than 818%. [11] While 2018 is highly unlikely to become Biogen's best year yet, if those results are positive, 2019 or 2020 could be. [11] I'd put the question of whether 2018 will be Biogen's (NASDAQ: BIIB) best year yet in the latter category. [11]

Ocrevus has already taken market share away from Biogen's Tysabri, and, to a lesser extent, Tecfidera. [11] Biogen's entire MS franchise generates 85% of total revenue. [11]

RANKED SELECTED SOURCES(33 source documents arranged by frequency of occurrence in the above report)

1. (18) BIIB Stock Price - Biogen Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

2. (16) Will 2018 Be Biogen Inc.'s Best Year Yet? | Business Markets and Stocks News |

3. (14) Biogen Has Achieved A Major Turnaround Event For The Treatment Of Alzheimer's - Biogen Inc. (NASDAQ:BIIB) | Seeking Alpha

4. (13) Biogen - BIIB - Stock Price & News | The Motley Fool

5. (13) NASDAQ:BIIB - Stock Price, News, & Analysis for Biogen

6. (10) AbbVie Launches, Biogen Tweaks Alzheimer's Collaborations | GEN

7. (9) Biogen, AbbVie pull MS drug after several patients suffer brain inflammation - The Boston Globe

8. (9) Biogen Stock Upgraded On Hope For Alzheimers Disease Treatment

9. (8) Biogen uk address

10. (6) Biogen shares soar on successful Alzheimer's drug trial

11. (5) Biogen Earnings: MS Meltdown Coming - Bloomberg

12. (4) Biogen Inc. - NASDAQ:BIIB - Stock Quote & News - TheStreet

13. (4) Biogen Inc (BIIB.O) Quote|

14. (3)

15. (3) Biogen Alzheimer drug success and the long tail of dementia drug fails

16. (3) Report: Biogen CEO eyes medical device market | Drug Delivery Business

17. (3) Earnings Preview: What To Expect From Biogen On Thursday

18. (3) • Biogen revenue and net income 2007-2017 | Statistic

19. (2) Experimental Treatments for Alzheimers Disease - Treatments That Target Beta-Amyloid Protein - Alzheimers News Today

20. (2) Biogen (BIIB) Market Valuation Declined While Altrinsic Global Advisors Trimmed Its Holding; Holder Naples Global Advisors Has Increased Aflac (AFL) Position | K Reviewer

21. (2) Biogen launches new app, Aby, for patients with MS | MobiHealthNews

22. (2) Biogen False Claims Act Suit Largely Survives Dismissal In Federal Court - Lexis Legal News

23. (1)

24. (1)

25. (1)

26. (1) Whittier Trust Co Has Trimmed Biogen Idec (BIIB) Stake; Xylem Inc. (XYL) Covered By 2 Bulls | The D Minute

27. (1) BIIB Stock Price & News - Biogen Inc. - Barron's

28. (1) Biogen Idec Inc. (NASDAQ:BIIB) - PreMarket Prep Recap For July 6: Digesting Biogen's News With Adam Feuerstein; A Sector Breakdown With Dan Russo | Benzinga

29. (1) Biogen Inc. - Company Profile - BioCentury - BCIQ

30. (1) Biogen Inc | $BIIB Stock | Shares Jump On Positive Final Analysis On Alzheimer Drug - News & Reviews

31. (1) Biogen | Neurological, Autoimmune and Rare Diseases


33. (1) Biogen Must Face FCA Suit Minus 17 State-Level Claims - Law360

Skip to toolbar